22 March 2019 - Deborah Wilkes
Sandoz and Allergan have announced people changes while the US Consumer Healthcare Products Association (CHPA) has honoured a longtime industry leader.
Chief executive leaves Sandoz
Novartis has announced Richard Francis will step down as chief executive officer of its Sandoz division at the end of March 2019.
Francesco Balestrieri – currently region head Europe at Sandoz – has been appointed ad-interim chief executive officer. He will report to Vas Narasimhan, chief executive officer of Novartis.
Narasimhan thanked Francis for his strong leadership of Sandoz over the past five years. He said Francis had decided for "personal reasons" that he couldn't commit to stay with Sandoz until the multi-year transformation programme and move towards greater autonomy had been completed.
Allergan to separate chairman and CEO
Allergan has promised to elect an independent chairman of the Board after its next leadership change. The move follows pressure from hedge fund Appaloosa to separate the roles of chairman and chief executive officer.
US CHPA honours Tim Hayes
The US Consumer Healthcare Products Association (CHPA) has presented the Ivan D Combe Lifetime Achievement Award to Tim Hayes who spent 25 years with Bayer. Before leaving the company in 2017, he rose to the position of president of Bayer Healthcare's North American Consumer Care business.
Hayes chaired four different CHPA committees – including the finance, planning and personnel committees – and was chair of the Board of Directors from 2004-2006.
The CHPA says the annual award recognises the "outstanding work and contributions of individuals whose actions have created a lasting impact on the people and the affairs of the consumer healthcare sector, and who have directly improved self-care for US consumers".
Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions
CLICK HERE TO FIND OUT MORE